HUSOVÁ, Libuše, Petr HUSA and Tomáš BRYCHTA. Mass ascites in Mulibrey nanism. Journal of Pediatric Endocrinology and Metabolism. Tel Aviv: Freund Publishing House Ltd., 2010, vol. 23, No 9, p. 863-865. ISSN 0334-018X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Mass ascites in Mulibrey nanism
Name in Czech Masivní ascites u pacienta s Mulibrey syndromem
Authors HUSOVÁ, Libuše (203 Czech Republic, guarantor), Petr HUSA (203 Czech Republic) and Tomáš BRYCHTA (203 Czech Republic).
Edition Journal of Pediatric Endocrinology and Metabolism, Tel Aviv, Freund Publishing House Ltd. 2010, 0334-018X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Israel
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.887
RIV identification code RIV/00216224:14110/10:00044628
Organization unit Faculty of Medicine
UT WoS 000282928800003
Keywords (in Czech) Mulibreysyndrom;ascites;Wilmsův tumor;konstriktivní perikarditida
Keywords in English Mulibrey nanism; Ascites; Wilms tumor; Constrictive pericarditis
Tags International impact, Reviewed
Changed by Changed by: prof. MUDr. Petr Husa, CSc., učo 945. Changed: 1/9/2010 08:30.
Abstract
Mulibrey nanism is a rare inherited disease characterized by growth failure and multi-organ manifestations. Mulibrey nanism is extremely rare in the Czech Republic,only this one patient has been reported yet. Mass ascites was the main clinical finding in this 22-year-old male patient. Combined treatment with spironolactone and furosemide improved significantly the patients quality of life and allowed conservative treatment of ascites with no need of repeated punctures. Current clinical status of the patient was satisfactory but various complications in the future are very probable because this patient has multiple organs, especially cardial, impairment.
Links
MUNI/A/1006/2009, interní kód MUName: Nové diagnostické a léčebné postupy u metabolických chorob
Investor: Masaryk University, Category A
PrintDisplayed: 28/9/2024 06:08